Get the Stockscreener App
6.81
3.68%
-0.26
After Hours:
6.81
4 D Molecular Therapeutics Inc stock is traded at $6.81, with a volume of 517.29K.
It is down -3.68% in the last 24 hours and up +10.73% over the past month.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
See More
Previous Close:
$7.07
Open:
$7.07
24h Volume:
517.29K
Relative Volume:
0.48
Market Cap:
$318.04M
Revenue:
$20.72M
Net Income/Loss:
$-100.84M
P/E Ratio:
-2.5602
EPS:
-2.66
Net Cash Flow:
$-78.56M
1W Performance:
-6.33%
1M Performance:
+10.73%
6M Performance:
+60.61%
1Y Performance:
-57.20%
1-Day Range:
$6.65
$7.07
1-Week Range:
$6.65
$7.40
52-Week Range:
$2.235
$17.41
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Name
4 D Molecular Therapeutics Inc
Sector
Industry
Phone
(510) 505-2680
Address
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
6.81 | 324.12M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Nov-21-24 | Initiated | Morgan Stanley | Underweight |
| Sep-23-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Apr-15-24 | Initiated | Barclays | Overweight |
| Feb-07-24 | Resumed | Goldman | Buy |
| Oct-26-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-18-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-18-22 | Initiated | H.C. Wainwright | Buy |
| Nov-15-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-12-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-22-22 | Initiated | Jefferies | Buy |
| Jan-04-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | BofA Securities | Buy |
| Jan-05-21 | Initiated | Evercore ISI | Outperform |
| Jan-05-21 | Initiated | Goldman | Neutral |
View All
4 D Molecular Therapeutics Inc Stock (FDMT) Latest News
4DMT Announces New Employment Inducement Grants - GlobeNewswire
Biotech Leader 4DMT Issues 40,900 Restricted Stock Units to Attract Key Non-Executive Talent - Stock Titan
Building trade automation scripts for 4D Molecular Therapeutics Inc.2025 Risk Factors & AI Powered Market Entry Strategies - Newser
How moving averages guide 4D Molecular Therapeutics Inc. tradingWeekly Trade Recap & Free High Return Stock Watch Alerts - Newser
4D Molecular Therapeutics Inc. stock trendline breakdownQuarterly Earnings Report & Fast Exit/Entry Strategy Plans - Newser
Should you wait for a breakout in 4D Molecular Therapeutics Inc.Market Weekly Review & Safe Capital Growth Tips - Newser
Visual analytics tools that track 4D Molecular Therapeutics Inc. performancePortfolio Value Report & Risk Adjusted Swing Trade Ideas - Newser
Cubist Systematic Strategies LLC Sells 364,659 Shares of 4D Molecular Therapeutics, Inc. $FDMT - Defense World
Ranking 4D Molecular Therapeutics Inc. among high performing stocks via toolsJuly 2025 Sector Moves & Stepwise Entry/Exit Trade Alerts - Newser
Chart based exit strategy for 4D Molecular Therapeutics Inc.Weekly Trend Summary & Risk Managed Investment Strategies - Newser
What indicators show strength in 4D Molecular Therapeutics Inc.Global Markets & Risk Controlled Daily Plans - Newser
Volume spikes in 4D Molecular Therapeutics Inc. stock – what they mean2025 Market Trends & Verified Entry Point Signals - Newser
GenVivo Strengthens Oncology Leadership with Appointment of Noriyuki Kasahara, M.D., Ph.D., as Chief Scientific Officer - GlobeNewswire Inc.
Regression analysis insights on 4D Molecular Therapeutics Inc. performanceAnalyst Upgrade & Verified Swing Trading Watchlists - Newser
What candlestick patterns are forming on 4D Molecular Therapeutics Inc.Weekly Profit Report & Growth Focused Entry Reports - Newser
How to track smart money flows in 4D Molecular Therapeutics Inc.Quarterly Profit Report & Reliable Trade Execution Plans - Newser
Is 4D Molecular Therapeutics Inc. a candidate for recovery playPortfolio Return Report & Step-by-Step Trade Execution Guides - Newser
Is 4D Molecular Therapeutics Inc. meeting your algorithmic filter criteriaJuly 2025 EndofMonth & Reliable Trade Execution Plans - Newser
Can 4D Molecular Therapeutics Inc. hit a new high this monthJuly 2025 Highlights & Free Risk Controlled Daily Trade Plans - Newser
Detecting support and resistance levels for 4D Molecular Therapeutics Inc.Weekly Trend Recap & High Conviction Buy Zone Picks - Newser
How to escape a deep drawdown in 4D Molecular Therapeutics Inc.Weekly Profit Summary & Verified Entry Point Detection - Newser
Pattern recognition hints at 4D Molecular Therapeutics Inc. upsideDollar Strength & High Return Stock Watch Alerts - Newser
Reversal indicators forming on 4D Molecular Therapeutics Inc. stockWeekly Stock Summary & Consistent Profit Trade Alerts - Newser
Transcript : 4D Molecular Therapeutics, Inc. Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-09-2025 01 - MarketScreener
Real time social sentiment graph for 4D Molecular Therapeutics Inc.2025 Trading Volume Trends & High Accuracy Swing Trade Signals - Newser
Is 4D Molecular Therapeutics Inc. forming a bottoming baseWeekly Loss Report & Reliable Trade Execution Plans - Newser
Jim Cramer on 4D Molecular Therapeutics: “This is a Pure Spec” - MSN
Can machine learning forecast 4D Molecular Therapeutics Inc. recoveryJuly 2025 Decliners & Accurate Technical Buy Alerts - Newser
Chart based analysis of 4D Molecular Therapeutics Inc. trendsJuly 2025 Spike Watch & Long-Term Investment Growth Plans - Newser
Using Python tools to backtest 4D Molecular Therapeutics Inc. strategies2025 Market Trends & Community Supported Trade Ideas - Newser
Combining price and volume data for 4D Molecular Therapeutics Inc.July 2025 Highlights & Expert Approved Momentum Ideas - Newser
Combining machine learning predictions for 4D Molecular Therapeutics Inc.Trade Volume Report & Weekly Stock Breakout Alerts - Newser
X-linked retinitis pigmentosa Pipeline Analysis & Clinical Trials, 2025, DelveInsight | Biogen, 4 D Molecular therapeutics, Applied Genetics Technology Corporation - The Globe and Mail
Top chart patterns to watch in 4D Molecular Therapeutics Inc.2025 Market Sentiment & Verified Technical Trade Signals - Newser
4D Molecular Therapeutics, Inc. $FDMT Shares Acquired by Invesco Ltd. - Defense World
Is this a good reentry point in 4D Molecular Therapeutics Inc.Fed Meeting & High Return Stock Watch Alerts - Newser
Why 4D Molecular Therapeutics Inc. stock attracts strong analyst attentionMarket Trend Report & Weekly Setup with ROI Potential - 시사인 투데이
Exit strategy if you’re trapped in 4D Molecular Therapeutics Inc.Market Performance Recap & Stock Timing and Entry Methods - Newser
4D Molecular Therapeutics Inc. recovery potential after sell offJuly 2025 Intraday Action & Free Weekly Watchlist of Top Performers - Newser
Real time scanner hits for 4D Molecular Therapeutics Inc. explainedJuly 2025 Momentum & Safe Capital Growth Trade Ideas - Newser
Price momentum metrics for 4D Molecular Therapeutics Inc. explainedMarket Movement Recap & Fast Entry Momentum Alerts - Newser
Can 4D Molecular Therapeutics Inc. navigate macro headwindsJuly 2025 Summary & Fast Gaining Stock Reports - خودرو بانک
Can 4D Molecular Therapeutics Inc. lead its sector in growthMarket Risk Report & AI Forecasted Entry and Exit Points - خودرو بانک
Should you avoid 4D Molecular Therapeutics Inc. stock right nowQuarterly Trade Summary & Consistent Profit Trade Alerts - خودرو بانک
4 D Molecular Therapeutics Inc Stock (FDMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):